banda transcan 2 2016ul

Title: Integrative cancer-immunology and Immunoscore for cancer classification and immunotherapies.


Project Coordinator:
Jérôme GALON (France) INSERM UMRS1138-Centre de recherche des cordeliers, Paris


Project Partners:
Franck PAGES (France) Hopital Européen Georges Pompidou, Paris Cedex 15
Arndt HARTMANN (Germany) University of Erlangen, Erlangen
Iris NAGTEGAAL (The Netherlands) Radboud umc, Nijmegen
Paolo ASCIERTO (Italy) Instituto dei tumori Fondazione, Napoli
Dolores LOZANO (Spain) Universidad de Navarra, Pamplona


Project Abstract:
Advance in the accuracy of predicting the patient prognosis is required. Major recent advances were made demonstrating the major importance of infiltrating immune cells. We provided evidence that the type, the density and the location of immune cells within tumor strongly influence the outcome of colorectal cancer (CRC) patients (Pagès F et al, N Engl J Med 2005; Galon J et al, Science 2006; Pagès F et al, J Clin Oncol 2009; Mlecnik B et al, J Clin Oncol 2011, Bindea G et al. Immunity 2013). To translate this information to the clinic we developed an “Immunoscore” method based on the quantification of T cell subsets (CD3/CD8) in two tumor regions (core and invasive margin of tumors). Importantly, Dr Galon’s laboratory together with the Society for Immunotherapy of Cancer (SITC, USA) is promoting an international task force to validate the “Immunoscore” and its major prognostic value. This project represents a unique opportunity to investigate large European cohorts of patients from a multidisciplinary perspective using latest techniques to investigate the interplay between the tumor (genomic signature) and the host (standardized immune test, Immunoscore) (Galon J et et J Pathol 2013). Beyond the classical cancer staging, the Immunoscore will better predict the outcome of each patient (Prognostic aspect), the response to treatment (Theranostic aspect), at the time of diagnosis and during the course of the disease.

Project Summary:
Advance in the accuracy of predicting the patient prognosis is required. Major recent advances were made demonstrating the major importance of infiltrating immune cells. We provided evidence that the type, the density and the location of immune cells within tumor strongly influence the outcome of colorectal cancer (CRC) patients. To translate this information to the clinic we developed an “Immunoscore” method based on the quantification of T cell subsets (CD3/CD8) in two tumor regions  (core and invasive margin of tumors). Importantly, Dr Galon’s laboratory is promoting an international task force to validate the consensus “Immunoscore” and its major prognostic value (Galon J et et J Pathol 2013). This project represents a unique opportunity to investigate large European cohorts of patients from a multidisciplinary perspective using latest techniques to investigate the interplay between the tumor (genomic signature) and the host (standardized immune test, Immunoscore). Beyond the classical cancer staging, the Immunoscore will better predict the outcome of each patient (Prognostic aspect), the response to treatment (Theranostic aspect), at the time of diagnosis and during the course of the disease. Our results indicate that assessment of the immune status via Immunoscore provides a potent indicator of tumor recurrence beyond microsatellite-instability staging and mutations that could be an important guide for immunotherapy strategies. We showed a comprehensive intrametastatic immune quantification and major impact of Immunoscore on survival. Recent results to be published into The Lancet, validated the consensus Immunoscore for the prognostic classification of colon cancer (Pages et al. The Lancet 2018 in press).

 

(Project funded under JTC 2013)


TRANSCAN News

Launch of the call: JTC 2021
The new TRANSCAN-3 project consortium is launching the first Joint Transnational Call for proposals, co-funded by the European Commission, on:
"Next generation cancer immunotherapy: targeting the tumour microenvironment"

International Networking Event (virtual)
on 22 April 2021 hrs 9:00 CET
will focus on the forthcoming co-funded JTC 2021 on:
"Next generation cancer immunotherapy: targeting the tumour microenvironment" 
the event is organized by TUBITAK under the “Turkey in Horizon 2020 Phase II” Technical Assistance Project
in cooperation with TRANSCAN-3

ERA-NET Cofund TRANSCAN-3:
 Sustained collaboration of national and regional programmes in cancer research
is the new project funded by the European Commission under H2020  which started on 1st March 2021 and will last five years (G. A. no. 964264)

A TRANSCAN-2 brochure, highlighting key achievements, is available for download

 

eu flagship

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 643638.

Who's Online

We have 14 guests and no members online